The Use of Hyperbaric Oxygen Therapy the Following Amputation in Patients with Diabetes

Diyabet Hastalarında Amputasyon Sonrası Hiperbarik Oksijen Tedavisi Kullanımı

© Figen Aydın¹, © Mustafa İncesu², © Elif Ebru Özer¹, © Ahmet Kaya²

¹University of Health Sciences Turkey, İzmir Bozyaka Education and Research Hospital, Clinic of Underwater and Hyperbaric Medicine, İzmir, Turkey
²University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital, Clinic of Orthopedics and Traumatology, İzmir, Turkey

Cite as: Aydın F, İncesu M, Özer EE, Kaya A. The Use of Hyperbaric Oxygen Therapy the Following Amputation in Patients with Diabetes. J Tepecik Educ Res Hosp 2022;32(1):73-8

Abstract

Objective: Foot ulcers are a frequently seen complication in patients with diabetes, which progress with a long period of hospitalization, a high risk of amputation and amputation stump problems. However, there are very few studies in literature on this subject. Hyperbaric oxygen therapy (HBOT) is an adjuvant treatment method used in cases of diabetic foot ulcers and when wound healing is delayed.

Methods: The aim of this retrospective study was to present and discuss the results of 35 cases that underwent minor amputation because of diabetic foot ulcers and applied HBOT for delayed stump healing.

Results: The patients presented for HBOT at mean 33.1±42.55 days (range, 1-210 days) after amputation. Mean 29.77 (range, 5-45) sessions of HBOT were applied. Clinical healing was obtained without further amputation in 29 (82.86%) cases, further amputation was required in 4 (11.43%) cases and 2 (5.71%) patients terminated the therapy on their own request.

Conclusion: HBOT should be included within a multidisciplinary approach to be able to prevent healing problems following amputation in patients with diabetic foot ulcers.

Keywords: Diabetic foot ulcer, amputation, stump healing, hyperbaric oxygen therapy

Öz

Amaç: Ayak ülserleri diyabet hastalarında sık görülen komplikasyonlardan olup, uzun süre hastanede yatış, yüksek amputasyon riski ve amputasyon güdük sorunlarıyla seyreder. Buna karşılık literatürde bu konuda az sayıda çalışma bulunmaktadır. Hiperbarik oksijen tedavisi (HBOT) ise diyabetik ayak ülserinin ve amputasyon gecikmesi durumlarında kullanılan bir tedavi yöntemidir.

Yöntem: Bu retrospektif çalışmanın amacı, amputasyon sonrası HBOT tedavisini takip eden 35 hasta ile çalışmaktır. HBOT tedavisinin amputasyon sonrası amputasyon starede, hücrelere oksijenin sağlanması ve klinik iyileşmenin age geçmesini kolaylaştırmaktır.

Bulgular: Çalışma sonuçlarına göre, 29 hasta (82.86%) klinik iyileşme sağlandı ve amputasyonu tekrar etmeyi seçmek zorunda kaldılar. Diğer hastalar ise HBOT tedavisiyle iyileşmeye devam etti.

Sonuç: HBOT tedavisi, amputasyon sonrası iyileşme sorunlarının önlenmesi için önemli birスタイルastedir. Bu nedenle, HBOT tedavisi, amputasyon sonrası iyileşme sorunlarının önlenmesi için önerilmelidir.

Anahtar Kelimeler: Diabetik ayak ülseri, amputasyon, hiperbarik oksijen tedavisi, klinik iyileşme, hücrelere oksijenin sağlanması.
Introduction

The prevalence of diabetes is increasing rapidly throughout the world and foot ulcers are the leading cause of morbidity and mortality in these patients\(^{(1-3)}\). Foot ulcers develop at some point in the life of 25% of patients with diabetes and approximately half of these patients are hospitalized because of foot ulcers, of which 20% will undergo amputation\(^{(4,5)}\). Amputation associated with diabetic foot ulcers is generally applied in patients with more than one diabetic comorbidity\(^{(6)}\). Operation site problems following amputation prolong the length of stay in the hospital and antibiotic use and are a significant cause of morbidity causing further amputations\(^{(5-7)}\).

Hyperbaric oxygen therapy (HBOT) is a medical treatment method applied to the patient in a completely closed pressure chamber by inhalation of 100% oxygen intermittently at pressures higher than 1 atmosphere\(^{(8,9)}\). With this treatment, the oxygen level dissolved in the plasma increases and anti-edema, antitoxic, and anti-infectious effects are obtained\(^{(10,11)}\). HBOT also accelerates wound healing by increasing fibroblast proliferation, collagen synthesis, expression and fibrillization\(^{(12-15)}\). Angiogenesis formed during this treatment eliminates hypoxia in chronic ulcers. HBOT is widely used in cases of delayed wound healing, primarily in diabetic foot ulcers\(^{(8,13-15)}\).

There are few studies in the literature related to healing of the amputation stump site in patients with diabetes. Therefore, this study aimed to present the treatment results of patients applied with HBOT because of delayed healing following amputation due to diabetic foot ulcers.

Materials and Methods

This retrospective study included the data of 35 patients with diabetes who applied with HBOT for operation site complications following a minor amputation due to diabetic foot ulcers between 01.01.2017 and 31.12.2020. On presentation, the necessary consultations were made; laboratory and radiological tests and culture-antibiogram examinations of deep tissue samples were performed. HBOT was applied in a Barotech multi-person pressure chamber in our clinic, as a single session each day of 120 min at 2.4 ATA (absolute atmosphere), 5 days a week.

Approval for the study was granted by the Clinical Research Ethics Committee of University of Health Sciences Turkey, İzmir Tepecik Education and Research Hospital (decision no: 2021/02-46, dated: 22.02.2021).

Statistical Analysis

Statistical analyses were performed using Statistical Package for the Social Sciences version 18.0 for Windows. Categorical variables were expressed as numbers or percentages, whereas continuous variables were expressed as mean ± standard deviation.

Results

The evaluation was made of 35 patients, comprising 29 (82.86%) males and 6 (17.14%) females with a mean age of 60.7 ± 9.78 years. All the patients were diagnosed with type 2 diabetes and 94.3% were under intensive insulin treatment. The clinical characteristics of the patients are shown in Table 1.

The micro-organisms most often determined in the deep tissue cultures were *Pseudomonas aeruginosa* (62.5%), *Staphylococcus aureus* (29.2%) and others (*E. coli* and *Klebsiella*) (8.3%). The patients received mean 29.77 (range, 5-45) sessions of HBOT and no complications were observed during the therapy sessions. Following the treatment, clinical healing was obtained without any additional surgical intervention in 29 (82.86%) cases (Figure 1a-e), further amputation was required in 4 (11.43%) cases and 2 (5.71%) patients terminated the treatment on their own request.

Discussion

More than 60% of all non-traumatic lower extremity amputations are applied to patients with diabetes and diabetics have a risk of amputation 6-10-fold higher than non-diabetics\(^{(16,17)}\). Major complications following amputation are stump infection, pain, tissue necrosis, edema, osteomyelitis, hematoma, opening of the stump and further amputations\(^{(8,7)}\). There are very few data in the literature related to wound healing following amputation. In a retrospective study of 101 cases with diabetes and vasculopathy, it was reported that these patients had a high risk of complications because of ulceration and gangrene of transmetatarsal amputation and the most important cause of morbidity was end-stage renal failure\(^{(18)}\). In another study, the stump infection was reported in 22% of lower extremity amputations, opening of the stump was observed in 16% of the amputations, and these complications significantly prolonged the length of stay in the hospital and required a longer period of broad-spectrum antibiotics in late stump infections including osteomyelitis\(^{(19)}\). There are also studies in literature that have reported that prophylactic antibiotic uses reduced stump infections and re-amputation rates and shortened the length of stay in the hospital\(^{(19-22)}\).
Armstrong et al.\(^{(3)}\) reported that the leading factors preventing healing within 1 year in 77% of diabetic foot ulcers were advanced end-organ disease (congestive heart failure, peripheral artery disease, or end-stage renal failure requiring renal replacement therapy) and the inability to walk independently. In the same study, it was stated that 40% of these ulcers recurred within 1 year, 60% within 3 years, and 65% within 5 years, and therefore it would be more appropriate to say remission rather than recovery. Natcher reported that minor amputations in cases of diabetic foot ulcers were effective for both preserving the extremity and for reducing morbidity and mortality, but stump complications were not mentioned in that study\(^{(22)}\).

There are several studies in the literature related to the use of HBOT for treating diabetic foot ulcers\(^{(23-30)}\). Some of these are prospective, randomized controlled studies that have reported that the addition of HBOT to standard treatments has shortened the healing period and the length of stay in the hospital. In several studies, extremity ischemia has been shown to be the most important factor determining the development of diabetic foot ulcers and poor prognosis for the healing of ulcers that have developed\(^{(31,32)}\). A meta-analysis

| Table 1. Clinical characteristics of the patients |
|-----------------------------------------------|
| Age (years)   | Minimum | Maximum | Mean ± SD |
| Duration of DM (years) | 0⁰ | 45 | 23.7±11.07 |
| Duration of the wound (weeks) | 1.43 | 34.29 | 16.67±11.45 |
| Post-op admission (days) | 1 | 210 | 33.1±42.55 |
| HbA1c (mg/100 mL) | 5.3 | 16 | 9.4±2.60 |
| White blood count | 6.16 | 16.58 | 11.49±2.82 |
| Erythrocyte sedimentation rate | 9.00 | 125.00 | 67.50±25.62 |
| C-reactive protein | 1.40 | 288.80 | 70.90±68.65 |
| HBOT session | 5 | 45 | 29.90 |

| Sex | Number | % |
|-----|--------|---|
| Female | 6 | 17.14 |
| Male | 29 | 82.86 |

| Type of DM | Minimum | Maximum | Mean ± SD |
|------------|---------|---------|-----------|
| Type 1 | 0 | 0.0 |
| Type 2 | 35 | 100.0 |

| Type of DM treatment | Minimum | Maximum | Mean ± SD |
|----------------------|---------|---------|-----------|
| OAD | 2 | 5.7 |
| Insulin | 33 | 94.3 |
| Neuropathy | 35 | 100.0 |
| Retinopathy | 25 | 71.4 |
| End-stage renal failure | 3 | 8.6 |
| Smoking | 27 | 77.1 |
| Coronary arterial disease | 21 | 60.0 |
| Peripheral arterial disease | 18 | 51.4 |

| Results | Minimum | Maximum | Mean ± SD |
|---------|---------|---------|-----------|
| Clinical healing | 29 | 82.86 |
| Further amputation | 4 | 11.43 |
| Terminated treatment | 2 | 5.71 |

DM: Diabetes mellitus, HbA1c: Glycosylated haemoglobin, OAD: Oral antidiabetic drug, 0⁰: Means undiagnosed diabetes mellitus before foot ulcer, SD: Standard deviation, HBOT: Hyperbaric oxygen therapy
published in 2021 reported that HBOT was effective in the full healing of diabetic foot ulcers and significantly reduced rates of major amputation and could therefore effectively be used as an adjuvant treatment for these ulcers\(^{(33)}\). Another systematic review presented a high level of evidence that when HBOT was included within a multidisciplinary wound care program, the risk of amputation was decreased in cases with diabetic foot ulcers complicated by surgical infection\(^{(34)}\). In another review, a significantly high rate of recovery was recorded for diabetic foot ulcers treated with HBOT and the major amputation rate was found to be significantly low\(^{(35)}\). In a previous retrospective study of 184 patients by the present authors, the major amputation rate was recorded as 4.9% in diabetic foot ulcers treated with HBOT\(^{(27)}\). In another meta-analysis that investigated the efficacy of HBOT in diabetic foot ulcers with arterial insufficiency, the addition of HBOT to standard treatments was reported to be helpful in reducing amputation rates\(^{(36)}\). The efficacy of HBOT investigated according to the Wagner classification in another study and the treatment was determined to significantly increase wound healing in grade 3 and 4 ulcers\(^{(37)}\).

### Study Limitations

This study has some limitations. The most important one is the absence of the control group. Thus, randomization could not be realized. Moreover our study had a retrospective design.

### Conclusion

In the current retrospective study of 35 patients, clinical healing was obtained without any further amputations.
in 29 cases and in 4 cases, re-amputation was required. No statistically significant difference was determined between the recovered group and those who required further amputation regarding age, duration of diabetes, and laboratory values, whereas the patients with further amputation were seen to have presented later with advanced end-organ failure (hemodialysis because of end-stage renal disease, congestive heart failure, and occlusions at the level of femoral and popliteal arteries shown on angiography). There was no difference between the two groups with respect to the number of HBOT sessions applied.

Although conducted retrospectively with a limited number of patients, the results of this study with findings in the literature demonstrate that the addition of HBOT to standard treatments can contribute to the healing of stump complications following amputation. Nevertheless, there is a need for further prospective, controlled studies on this subject.

Ethics

Ethics Committee Approval: Approval for the study was granted by the Clinical Research Ethics Committee of University of Health Sciences Turkey, Izmir Tepecik Education and Research Hospital (decision no: 2021/02-46, dated: 22.02.2021).

Informed Consent: Retrospective study.

Peer-review: Externally and internally peer-reviewed.

Authorship Contributions

Concept: F.A., M.İ., E.E.Ö., A.K., Design: F.A., M.İ., E.E.Ö., A.K., Data Collection or Processing: F.A., M.İ., E.E.Ö., A.K., Analysis or Interpretation: F.A., M.İ., E.E.Ö., A.K., Writing: F.A., M.İ., E.E.Ö., A.K.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults Eur J Epidemiol 2013;28:169-80.
2. Saltoğlu N, Köççüoğlu Ö, Baktiroğlu S, et al. Diagnosis, treatment and prevention of diabetic foot wounds and infections: Turkish consensus report. Klinik Derg 2015;28:2-34.
3. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367-75.
4. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293:217-28.
5. Senneville É, Lipsky BA, Abbas ZG, et al. Diagnosis of infection in the foot in diabetes: a systematic review. Diabetes Metab Res Rev 2020;36(Suppl 1):e3281.
6. Ashraff S, Siddiqui MA, Santos D, Carlone T. Complications of stump healing among diabetic population. Turk J Endocrinol Metab 2018;22:91-7.
7. Dunkel N, Belaieff W, Assal. M, et al. Wound dehiscence and stump infection after lower limb amputation: risk factors and association with antibiotic use. J Orthop Sci 2012;17:588-94.
8. Basset BE, Bennett PB. Introduction to the physical and physiological bases of hyperbaric therapy. In Hunt TK, Davis JC (eds). Hyperbaric oxygen therapy. Maryland, Undersea Medical Society Inc.; 1977. p. 11-24.
9. Çimşit M. Hiperbarik oksijenin fiziksel ve fizyolojik esasları. Hiperbarik Tıp. 1. Basım. Ankara, Eflatun Yayını; 2009. p. 23-34.
10. Mathieu J, Wattel F. Physiologic effects of hyperbaric oxygen on micro organisms and host defences against infection. In Mathieu D (ed). Handbook on Hyperbaric Medicine 1st ed. Netherlands, Springer Press.; 2006. p. 103-19.
11. Mooney I, La Motte J. A review of the potential to restore vision with stem cells. Clin Exp Optom 2008;91:78-84.
12. Knighton DR, Mechanism of wound healing. In Kindwall EP (ed). Hyperbaric Medicine Practice. Flagstaff USA, Best Publishing Company.; 3rd ed. 1994. p. 119-39.
13. Niinikonski J. Physiologic effects of hyperbaric oxygen on wound healing processes. In Mathieu D (ed). Handbook on Hyperbaric Medicine 1st ed. Netherlands, Springer Press.; 2006. p. 135-45.
14. Gordillo GM, Sen CK. Revisiting the essential role of oxygen in wound healing. Am J Surg 2003;186:259-63.
15. Zamboni WA, Browder LK, Martinez J. Hyperbaric oxygen and wound healing. Cln Plast Surg 2003;30:67-75.
16. Lipsky BA, Weigelt JA, Sun X, Johannes RS, Derby KG, Tabak YP. Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection. Diabetes Care 2011;34:1695-700.
17. Ahmad N, Thomas GN, Gill P, Torella F. The prevalence of major lower limb amputation in the diabetic and non-diabetic population of England 2003-2013. Diab Vasc Dis Res 2016;13:348-53.
18. Pollard J, Hamilton GA, Rush SM, Ford LA, Mortality and morbidity after transmetatarsal amputation: retrospective review of 101 cases. J Foot Ankle Surg 2006;45:91-7.
19. Kumar D, Mishra SR, Gupta AK, Shrma VP, Yadav G, Kumar S. Late stump infection of lower limb amputation in North India. Indian J Appl Res 2015;5:363-5.
20. McIntosh J, Earnshaw JJ. Antibiotic prophylaxis for the prevention of infection after major limb amputation. Eur J Vasc Endovasc Surg 2009;37:696-703.
21. Sadat U, Chaudhuri A, Hayes PD, Gaunt ME, Boyle JR, Varty K. Five day antibiotic prophylaxis for major lower limb amputation reduces wound infection rates and the length of in-hospital stay. Eur J Vasc Endovasc Surg 2008;35:75-8.
22. Nather A, Wong KL. Distal amputations for the diabetic foot. Diabet Foot Ankle 2013:4.
23. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer: A randomized study. Diabetes Care 1996;19:1338-43.
24. Doctor N, Pandya S, Supe A. Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med 1992;38:112-4.
25. Abidia A, Laden G, Kukan G, et al. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003;25:513-8.
26. Kalani M, Jörneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications 2002;16:153-8.
27. Kaya A, Aydin F, Altay T, Karapinar L, Ozturk H, Karakuzu C. Can major amputation rates be decreased in diabetic foot ulcers with hyperbaric oxygen therapy? Int Orthop 2009;33:441-6.
28. Duzgun AP, Satir HZ, Ozozan O, Saylam B, Kulah B, Coskun F. Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg 2008;47:515-9.
29. Aydin F, Kaya A, Karapinar L, et al. IGF-1 Increases with hyperbaric oxygen therapy and promotes wound healing in diabetic foot ulcers. J Diabetes Res 2013;2013:6-1.
30. Faglia E, Favales F, Aldeghe A, et al. Change in major amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic determinants for major amputation. J Diabetes Complications 1998;12:96-102.
31. Ndosi M, Wright-Hughes A, Brown S, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med 2018;35:78-88.
32. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012;54:132-73.
33. Sharma R, Sharma SK, Mudgal SK, Jelly P, Thakur K. Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trials. Sci Rep 2021;11:2189.
34. Goldman RJ. Hyperbaric oxygen therapy for wound healing and limb salvage: a systemic review. PM R 2009;1:471-9.
35. Lui R, Li L, Yang M, Boden G, Yang G. Systematic review of the effectiveness of hyperbaric oxygen therapy in the management of chronic diabetic foot ulcers. Mayo Clin Proc 2013;88:166-75.
36. Brouwer RJ, Lalieu RC, Hoencamp R, van Hulst RA, Ubbink DT. A systematic review and meta-analysis of hyperbaric oxygen therapy for diabetic foot ulcers with arterial insufficiency. J Vasc Surg 2020;71:682-92.
37. Erdoğan A, Düzgün AP, Erdoğan K, Özkan MB, Coskun F. Efficacy of hyperbaric oxygen therapy in diabetic foot ulcers based on wagner classification. J Foot Ankle Surg 2018;57:1115-9.